The biopharmaceutical company AstraZeneca has received US approval for its Datroway treatment for patients with previously treated advanced EGFR-mutated non-small cell lung cancer.
The biopharmaceutical company has entered a strategic research collaboration with CSPC Pharmaceuticals to advance the discovery and development of novel oral candidates for chronic diseases.
The CFO of the pharmaceutical company has gifted 200 American Depositary Shares to charity.
The healthcare company has received European approval for a fixed-duration regimen of its Calquence drug in combination with other therapies to treat chronic lymphocytic leukemia.
The biopharmaceutical company's cancer drug Imfinzi has been recommended for approval in the EU for the treatment of muscle-invasive bladder cancer.
The biopharmaceutical company has announced changes to the shareholding of its Chief Executive Officer.
The major pharmaceutical company announces its CEO has been appointed to the board of Agilent Technologies.
The major pharmaceutical company has completed the acquisition of a biotechnology firm, expanding its cell therapy capabilities and pipeline.
The biopharmaceutical company reported positive results from a late-stage trial evaluating its cancer drug Imfinzi in patients with early-stage bladder cancer.
The biopharmaceutical company reported positive results from a Phase III trial of its HER2-directed antibody drug conjugate Enhertu in patients with high-risk, early-stage HER2-positive breast cancer.